(Adds details about pipeline, comment from CEO)
ZURICH, April 18 (Reuters) – Swiss biotech Idorsia said on Thursday that all four clinical trials of its late-stage drug hopefuls were “on track” as it confirmed expectations of spending 570 million Swiss francs ($564 million) in the current year on the projects.
Idorsia’s first-quarter net loss widened to 106 million francs, from 79 million in the period in 2018. The Allschwil-based company had total liquidity of 1.1 billion francs as of March 31, down from 1.2 billion at the end of last year.
Shares in the company were down 2.6 percent at 0716 GMT.
Idorsia founder Chief Executive Jean-Paul Clozel has Phase III studies of drugs for insomnia, rare Fabrys disease, hypertension and brain bleeding. After raising